Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
    • Technology
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
    • Podcast
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

First Treg Immunotherapy Approved to Improve Chronic GVHD-Free Survival in Blood Cancer Patients

FDA has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.

New Healthcare Advisory Committee Created to Improve Patient Care

Doctor listening to a patient's heart with stethoscope.

The Healthcare Advisory Committee will develop actionable policy solutions, advance accountability for safety and more.

New CMS Proposal to Speed up Patient Access to Drugs

A pharmacist consulting a patient.

The new federal advisory body, the Healthcare Advisory Committee, will provide advice on modernizing healthcare in the U.S.

FDA Approves Gene Therapy for Rare Immune Disorder (2026)

Nurse wearing a medical mask preparing an IV solution.

FDA-approved Kresladi (marnetegragene autotemcel) is the first gene therapy treating leukocyte adhesion deficiency type I (LADI).

High-Dose Flu Vaccine Significantly Lowers Risk of Developing Alzheimer’s (2026)

Concept image of brain synapses.

A UTHealth study found adults 65 and older had a lower risk of developing Alzheimer’s disease after receiving a high-dose flu vaccine.

CMS Launches First Wave of HealthTech Ecosystem Tools

Medical provider in scrubs holding a tablet with medical concept art above.

CMS has launched HealthTech tools to streamline care and digitize the patient experience.

CMS Proposes to Lower Costs for Hip, Knee and Ankle Replacements

Concept art of joint replacement.

A new CMS Comprehensive Care for Joint Replacement (CJR) Model proposal could lower costs nationwide for Medicare beneficiaries undergoing knee, hip and ankle replacements.

Flu Vaccine, Even with Infection, Reduces Risk of Heart Attack and Stroke

Man wearing a green button-up sweater clutching at his chest.

The Statens Serum Institut in Copenhagen found that flu vaccines may protect against heart attack and stroke, even if the flu is still developed after vaccination.

FDA Approves Drug to Treat Hunter Syndrome

Medical practitioner in a stethoscope holding an orange card with the phrase "Hunter Syndrome" written in white.

Avlayah (tividenofusp alfa-eknm) has been FDA-approved to treat some individuals with Hunter Syndrome (Mucopolysaccharidosis type II or MPS II).

Pain-Relieving Drug with Minimal Addictive Properties Discovered

Person lying down with foot resting on a physical therapy machine for knee surgery recovery.

The novel opioid DFNZ shows potential for pain and opioid use disorder without causing depressed breathing.

Next →
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Linkedin-in

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.